Safety Agreements & Outsourced PV: What It Means and Why It Matters

In the modern pharmaceutical business environment, many companies outsource parts (or all) of their pharmacovigilance (PV) operations — for example, adverse-event reporting, signal detection, database management, periodic safety reporting, etc. That outsourcing can help optimize costs, leverage external expertise, and allow companies to focus on core business functions. But outsourcing does not remove regulatory responsibility for safety; rather, it requires a formal binding agreement that clearly defines who is responsible for what.

These legally binding documents — often called Pharmacovigilance Agreements (PVAs), Safety-Data Exchange Agreements (SDEAs), or Drug Safety Agreements (DSAs) — delineate how PV tasks are delegated between the Marketing Authorization Holder (MAH) (or manufacturer) and third parties (distributors, local representatives, Contract Research Organizations — CROs — or dedicated PV service providers).

Such agreements ensure compliance with Good Pharmacovigilance Practice (GVP) requirements under global regulators (e.g., authorities following guidelines of European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), or comparable regulatory frameworks), helping to avoid regulatory findings during inspections.

Global Requirements — What Regulators Usually Expect

From the global regulatory perspective, PVAs are indispensable whenever a MAH outsources PV functions such as:

• Adverse-event (AE) / adverse-drug-reaction (ADR) reporting and case processing
• Signal detection and evaluation
• Periodic safety reports (e.g. PSURs / PBRERs / DSURs)
• Causality assessments, risk-management actions, safety communications

A robust PVA must clearly define:

• The PV tasks being delegated and those retained by the MAH
• Timelines and reporting flows
• Responsibilities for case collection, data quality, signal detection, aggregate reporting
• Obligations for regulatory compliance, audits/inspections, record-keeping, data privacy, etc. (VigiOps)

Furthermore, outsourcing PV should not lead to “loss of oversight”: the MAH (and its QPPV) remains ultimately responsible for safety and regulatory compliance globally. Thus, effective oversight, clear communication channels, periodic review of performance and compliance audits are part of good practice under global standards.

Local Context: Tanzania / East Africa — What the Regulations Require

In Tanzania, the regulatory landscape governing pharmacovigilance is anchored in the Tanzania Medicines and Medical Devices Authority (TMDA), under the framework of the Tanzania Food, Drugs and Cosmetics (Pharmacovigilance) Regulations, 2018.

Key obligations include:

• MAHs / manufacturers must establish and maintain a full PV quality system, including a dedicated focal person and a Pharmacovigilance System Master File (PSMF).
• They must collect, manage and submit safety data: Individual Case Safety Reports (ICSRs), periodic safety update reports (PSURs), and any other required safety documentation.
• There are defined requirements for reporting adverse events, product quality defects, medication errors, lack of efficacy etc. through the national system, involving healthcare providers, patients, MAHs, and importers.
• For imported products (or products with foreign MAH), the “local responsible person” (e.g. local distributor or representative) may take charge of PV obligations locally — but that must be clearly defined.

Moreover, under the regional East African Community (EAC) harmonization efforts, guidelines require that PV inspections (for MAHs or firms fulfilling MAH’s PV obligations) follow a risk-based schedule — typically every 2-3 years — whether local or foreign. Remote inspections may also be used when needed (e.g. for overseas MAHs).

What this means is: even if a company outsources PV tasks to a third-party provider (whether local or international), the regulatory responsibility remains with the MAH — and the outsourcing must be governed by a proper written agreement that complies with TMDA (and EAC) requirements.

Failure to establish such agreements (or failure to execute them properly) may result in non-compliance, potentially leading to regulatory actions under the 2018 PV regulations.

Challenges in the Tanzanian/East-African Setting

Even though the regulatory framework is in place, real-world implementation faces several challenges:

• A significant proportion of MAHs (especially for herbal products or small-scale local distributors) may not actively disseminate safety information, or maintain full PV systems. For example, a survey found many MAHs did not share any PV information to stakeholders.
• Limited local capacity: many health-care facilities, distributors, small importers/wholesalers may not have dedicated PV personnel; thus outsourced or third-party support becomes essential.
• Complexity in coordinating between national regulatory requirements (TMDA/PV regulations), regional harmonization (EAC), and international/global safety obligations for products marketed elsewhere — especially for multinational MAHs.
• Need for consistent quality, timeliness, data integrity, and regulatory compliance in safety reporting when PV tasks are outsourced across jurisdictions.

How Alcare Consultancy Supports Clients — Serving as Your PV Partner (including PVA Management)

As a consultancy specializing in regulatory support, product registration, pharmacovigilance and compliance — based in Dar es Salaam — Alcare Consultancy is well-positioned to help companies navigate the above challenges. Here’s how we assist clients in the role of a PV partner under QPPV oversight:

• Drafting and managing PVAs / Safety Agreements — We help you craft robust pharmacovigilance agreements (PVAs / DSAs / SDEAs) tailored to your business model (whether manufacturing, distribution, import-export, local representation, co-marketing, etc.), clearly delineating responsibilities, reporting flows, timelines, and compliance obligations (both globally and under Tanzanian / EAC law).
• Setting up and maintaining full PV systems — For companies without in-house PV infrastructure, we support establishment of a compliant PV quality system (including PSMF, SOPs, local PV focal person, safety data flow, documentation practices) that meets requirements of the Tanzania Food, Drugs and Cosmetics Act and 2018 PV regulations.
• PV operations outsourcing with oversight — We can serve as an outsourced PV “back-office”: collecting ADR/AE reports, processing ICSRs, preparing periodic safety reports (PSUR/PBRER), managing signal detection/reporting, coordinating with regulatory authorities (e.g. Tanzania Medicines and Medical Devices Authority (TMDA)) and local distributors/representatives — while keeping you (the MAH) fully compliant and in control.
• Regulatory compliance & inspection readiness — Given the risk of inspections (on-site or remote) as per EAC harmonization guidance, we ensure your PV documentation, agreements, safety database, case handling, and reporting history are fully audit-ready.
• Local representation and liaison with TMDA — For foreign MAHs or distributors, we act as local liaison or “responsible PV person,” ensuring local requirements (reporting, data submission, local contact points) are met.
• Training and capacity building — We provide training and awareness for local distributors, healthcare partners, pharmacists, and staff on PV responsibilities (ADR reporting, safety data collection, compliance), to foster a robust PV culture.
• Adaptation to global and regional standards — We help integrate global GVP requirements (as expected by EMA, FDA, or other regions where your products are marketed) with local Tanzanian / East-African regulatory obligations — offering harmonized PV operations across jurisdictions.

Why Having a PV Partner Matters — and Why You Should Consider Using Alcare Consultancy

Outsourcing PV tasks without a proper agreement and oversight may put your company at risk — regulatory non-compliance, delayed safety reporting, poor data quality, or even public health hazards. On the other hand, partnering with a consultancy like Alcare allows you to:

• Ensure compliance with both global and local PV regulations (TMDA, EAC, GVP)
• Maintain oversight and accountability through clear agreements and transparent workflows
• Leverage expertise (local context, regulatory requirements, reporting practices) without building a full in-house PV department
• Remain audit and inspection-ready, reducing regulatory and business risk

Given the complexity of PV — especially in a region like East Africa where capacity, infrastructure, and regulatory maturity vary — having a reliable PV partner is often the most pragmatic, efficient, and safe approach for MAHs, importers, distributors, or foreign manufacturers.

Ensuring Robust Safety Data Collection & Management — The Role of a QPPV

Pharmacovigilance (PV) does not end when a medicine is approved and marketed. In fact, the post-marketing phase is often the riskiest time — when rare, unexpected adverse drug reactions (ADRs) may emerge, under real-world conditions not reflected in clinical trials. Effective safety data collection and management is therefore foundational to the role of a Qualified Person for Pharmacovigilance (QPPV).

As QPPV, your duty is to ensure that all sources of safety data — spontaneous reports, literature, post-marketing studies, quality reports — are systematically captured, cleaned, assessed, and reported to authorities in compliance with global and local regulatory requirements.

Global Pharmacovigilance Expectations for Safety Data Collection

Globally, pharmacovigilance systems aim to enable early detection, assessment, and prevention of adverse drug reactions once a product is on the market. Key global requirements and good practices include:

• Multiple data sources: Safety data should be collected not only from spontaneous reports by healthcare professionals or patients/consumers, but also from scientific literature, observational studies, registries, post-authorization safety studies, and other real-world evidence.
• Standardised reporting and data exchange formats: For consistency and ability to pool data internationally, Individual Case Safety Reports (ICSRs) should follow recognized standards (e.g. the E2B format). This enables data sharing with global safety databases such as Uppsala Monitoring Centre (UMC) and its global ADR database VigiBase.
• Timely reporting and follow-up: Suspected ADRs — whether known or unknown, serious or not — should be reported as soon as possible. Prompt follow–up is necessary for incomplete or evolving cases (e.g. serious outcomes, lack of causality data, additional lab results).
• Comprehensive data capture: Reports should include as much detail as possible: patient demographics and history, drug details (brand name, dosage, route, start/stop dates), description of reaction (onset date, signs/symptoms), any concomitant medications, treatment given, outcome, and reporter details (while preserving patient confidentiality).
• Record-keeping, data quality, data management systems: MAHs (Marketing Authorization Holders) must maintain their own internal safety databases, ensure traceability, support causality assessment, signal detection, and periodic aggregate safety reporting (e.g. PSURs / PBRERs).

These expectations allow individual countries to integrate into global drug-safety monitoring networks, and enable identification of safety signals across populations and regions.

Tanzanian / East-African Requirements — What Clients Must Know Locally

In Tanzania and the broader East-Africa region, safety data collection and reporting are governed by regulations set by the Tanzania Medicines and Medical Devices Authority (TMDA), under the legal framework of the Tanzania Food, Drugs and Cosmetics Act.

Key Local Requirements & Practicalities

• Broad scope of reporting: Under current guidelines, ADR reporting covers not only medicines, but also herbal medicines, vaccines, biological products, medical devices, diagnostics, and cosmetics.
• Who can report: Reporting is not limited to healthcare providers. Patients/consumers and marketing authorization holders (MAHs) may also report suspected ADRs or safety issues.
• Multiple reporting channels: TMDA supports paper-based (yellow-card) reporting, as well as modern electronic systems to improve accessibility. These include an online reporting portal, mobile-phone/USSD reporting, toll-free hotline, and a mobile app.
• Minimum data requirements: Reports must include key patient information, suspected drug details (name, dose, route, dates), reaction description (onset date, symptoms), concomitant conditions or medications, outcome, and reporter contact. Each case should have a separate form.
• Reporting of all suspected ADRs: All suspected ADRs or adverse events should be reported — whether known or unknown, serious or minor — to facilitate detection of new or rare safety issues.
• Active surveillance in addition to spontaneous reporting: Besides spontaneous reporting, more structured methods — such as cohort event monitoring, pregnancy registries, drug utilization studies — may be used, especially for high-risk products or new medicines.
• Timely submission to TMDA: Once a suspected ADR is identified, the report should reach TMDA promptly (for serious reactions, expedited reporting may be required).
• Commitment to building PV culture: Challenges remain — under-reporting due to lack of awareness, limited resources, weak distribution of reporting tools, and inconsistent participation by MAHs.

Recognizing these realities is essential for any company marketing or distributing medicinal or health-related products in Tanzania.

Challenges — Why Safety Data Collection is Often Weak in Tanzania / East Africa

Despite the regulatory framework, many obstacles hinder effective safety data collection in Tanzania (and similar settings):

• Under-reporting: Many ADRs go unreported because health-care professionals may not prioritize reporting, or lack awareness/training. Likewise, MAHs may not systematically collect or report cases.
• Limited infrastructure: Some health facilities — especially in remote or rural areas — may lack access to electronic reporting tools or even paper-based forms (“yellow cards”).
• Insufficient resources & capacity for follow-up and causality assessment: Serious ADRs may require detailed follow-up, lab investigations, outcome monitoring — but resource constraints may make this difficult.
• Low engagement by MAHs / manufacturers: Without strong PV obligations or enforcement, some MAHs may neglect active safety monitoring post-marketing.
• Data management & quality issues: Inconsistent or incomplete reporting — missing fields, poor patient history, lack of outcome data — undermines the value of submitted safety data.

These gaps compromise the ability of the national PV system to detect safety signals — which may affect patient safety and public health.

How Alcare Consultancy Supports Clients — Bridging Global Standards & Local Realities

This is where a specialized consultancy like Alcare steps in. As a firm with expertise in regulatory affairs and pharmacovigilance — and based in Dar es Salaam — Alcare Consultancy can play a pivotal role in helping companies meet both global and Tanzanian/East-African PV obligations. Here’s how:

✅ Building & Maintaining Robust PV Systems

• Establishment of internal safety-reporting infrastructure: Alcare helps clients set up safety data collection workflows — standard operating procedures (SOPs), internal case-reporting mechanisms, databases — aligned with global good practices (e.g. E2B-compliant ICSRs) and ready for integration with national systems.
• Training & sensitization: Through training of staff (pharmacists, sales teams, distributors) on ADR reporting, follow-up, data capture and quality standards — helping overcome under-reporting due to lack of awareness or capacity.
• Ensuring compliance with TMDA regulations: Alcare guides clients through the requirements of the Tanzania Medicines and Medical Devices (Pharmacovigilance) Regulations, 2018, the national PV guidelines, reporting timelines, and correct use of forms / electronic systems.

📤 Facilitating Regulatory-Ready Reporting & Data Submission

• Case processing and submission: On behalf of clients, Alcare can process Individual Case Safety Reports (ICSRs), ensure completeness and quality, and submit to Tanzania Medicines and Medical Devices Authority (TMDA) through appropriate channels — whether paper, online portal, USSD, or mobile app.
• Aggregate data management and analysis: Maintain internal safety databases for clients, enabling periodic review, detection of safety trends or signals, preparation of safety summaries and reports (e.g. PSURs), even before regulatory deadlines.
• Causality assessment support: Assist in follow-up investigations, collection of additional information (medical history, lab data, concomitant drugs), and causality assessment — which is often challenging for companies lacking in-house PV experts.

📚 Advising Clients on Risk-Based Surveillance & Post-Marketing Studies

• Design and execution of active surveillance (where needed): For new or high-risk products (e.g. biologicals, vaccines, high-dose therapies), Alcare can help design cohort monitoring, registries, drug utilization studies, or other post-marketing safety studies, to generate robust real-world evidence.
• Integration with global safety databases: For products intended for multiple markets, Alcare ensures that safety data collected locally is compatible with international reporting standards (e.g. E2B), enabling seamless submission to global databases like VigiBase, and compliance with global MAH obligations.

🛡️ Risk Management and Regulatory Preparedness

• Proactive risk-minimization planning: Based on safety data trends, Alcare can assist clients in developing risk-management plans, updating product safety information (label, leaflet), advising on targeted safety communications, or withdrawal/recall if needed.
• Regulatory audit readiness: Regular internal audits of the PV system (data management, reporting, documentation) to ensure the client is inspection-ready and meets both national and international pharmacovigilance expectations.

Why Effective Safety Data Collection Matters — Beyond Compliance

Collecting and managing safety data is not just a regulatory checkbox. For manufacturers, distributors, or marketing authorization holders — especially in emerging markets such as Tanzania and East Africa — robust pharmacovigilance offers real value:

• Protecting patient safety and public health: Early detection of ADRs can prevent harm, reduce hospitalisation or mortality, and build trust in healthcare.
• Safeguarding brand reputation and market sustainability: Companies that monitor safety proactively and respond quickly to signals demonstrate responsibility — reducing risk of withdrawal, litigation, or regulatory actions.
• Supporting evidence-based decision-making and product life-cycle management: Real-world safety data can guide dosage adjustments, risk-minimization strategies, or decisions about continuation of products in certain populations.
• Enabling global market access: For companies exporting or operating in multiple countries, alignment with global PV standards (e.g. ICH, ADR reporting databases) is often required for regulatory compliance abroad.

With local realities — weak reporting culture, resource constraints, under-reporting — the value of an experienced PV partner (like Alcare Consultancy) in setting up and operating a solid safety data collection and management system becomes even more evident.

Conclusion

Safety data collection and management is a cornerstone of effective pharmacovigilance. As a QPPV (or as a company under QPPV oversight), ensuring robust, compliant, and responsive data collection systems — spanning spontaneous reporting, active surveillance, follow-up, data analysis, and regulatory submission — is not optional; it is essential for patient safety and product sustainability.

For companies operating in Tanzania and East Africa, partnering with a consultancy like Alcare can bridge the gap between global best practices and local regulatory/nearly-real world constraints — enabling compliance, risk-mitigation, and continuity.